What is Lexicon Pharmaceuticals Inc (LXRX) stock price today?

Lexicon Pharmaceuticals Inc (LXRX) currently trades at $1.61 per share. The stock has a market capitalization of $716.02M and a P/E ratio of —x.

Is LXRX stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Lexicon Pharmaceuticals Inc has a Smart Value Score of 15/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 4/9 and Altman Z-Score is -8.22.

What is Lexicon Pharmaceuticals Inc's revenue and earnings?

Lexicon Pharmaceuticals Inc has trailing twelve-month (TTM) revenue of $49.80M with profit margins of -101.10%. Earnings per share (EPS) is $-0.14.

Is Lexicon Pharmaceuticals Inc financially healthy?

Lexicon Pharmaceuticals Inc's Piotroski F-Score is 4/9 (moderate financial health). The Altman Z-Score of -8.22 places it in the distress.

LXRX

Lexicon Pharmaceuticals Inc

NASDAQ: LXRX · HEALTHCARE · BIOTECHNOLOGY

$1.61

+3.87% today

Updated 2026-04-30

Market cap

$716.02M

P/E ratio

—

P/S ratio

14.38x

EPS (TTM)

$-0.14

Dividend yield

—

52W range

$1 – $2

Volume

2.4M

Market cap

$716.02M

P/E ratio

—

P/S ratio

14.38x

EPS (TTM)

$-0.14

Dividend yield

—

52W range

$1 – $2

Volume

2.4M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

3.0

Growth

6.5

Quality

2.0

Profitability

5.0

Valuation

C+

4/9

Piotroski F-Score

Moderate

-8.2

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$3.36

+108.70%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy2 Buy2 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Debt/equity 0.48x — low leverage

Risks

- Altman Z -8.22 — distress zone

- Thin margins at -101.10%

- Negative free cash flow $-17.23M

- Revenue declining -79.30% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$139000.00	$1.20M	$31.08M	$49.80M	$49.80M
Net income	$-101.94M	$-177.12M	$-200.40M	$-50.34M	$-15.53M
EPS	—	—	—	—	$-0.14
Free cash flow	$-90.18M	$-162.37M	$-179.81M	$-67.85M	$-17.23M
Profit margin	-73,341.01%	-14,710.88%	-644.78%	-101.08%	-101.10%

Recent insider activity

Date	Insider	Type	Shares	Price
2026-02-28	MCDERMOTT, WENDY	Sale	144,393	—
2026-02-28	MCDERMOTT, WENDY	Sale	52,316	—
2026-02-28	MCDERMOTT, WENDY	Sale	27,697	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
LXRX	$716.02M	15	3.0	2.0	5.0	6.5	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Lexicon Pharmaceuticals Inc trades at $1.61. Our Smart Value Score of 15/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -8.22, it sits in the distress. TTM revenue stands at $49.80M. with profit margins at -101.10%.

Frequently asked questions

What is Lexicon Pharmaceuticals Inc's stock price?

Lexicon Pharmaceuticals Inc (LXRX) trades at $1.61.

Is Lexicon Pharmaceuticals Inc overvalued?

Smart Value Score 15/100 (Grade F, Strong Sell).

What is the price target of Lexicon Pharmaceuticals Inc (LXRX)?

The analyst target price is $3.36, representing +108.7% upside from the current price of $1.61.

What is Lexicon Pharmaceuticals Inc's revenue?

TTM revenue is $49.80M.

Piotroski F-Score?

4/9 — moderate financial health.

Altman Z-Score?

-8.22 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

www.lexpharma.com

Quick metrics

P/S ratio14.38x

ROE-39.70%

Beta0.95

50D MA$1.63

200D MA$1.37

Shares out0.42B

Float0.42B

Short ratio—

Avg volume2.4M

Performance

1 week-7.74%

1 month-0.64%

3 months+7.64%

YTD+34.78%

1 year—

3 years—

5 years—

Compare

LXRX vs LLY →LXRX vs JNJ →LXRX vs ABBV →Stock screener →